Monitor 2026 quarterly reports to assess the success of management's strategy to grow the core biologics business organically after significant revenue declines from divestitures and lost licensing deals. The company's ability to maintain profitability on a much smaller revenue base will be critical.
Price Chart
Executive Summary
Xtant Medical reported full-year 2025 revenue of $133.9 million, a 14% year-over-year increase, and achieved profitability with $5.0 million in net income. However, the company guided 2026 revenue down to $95-$99 million due to the divestiture of non-core assets and cessation of license revenue, overshadowing the strong 2025 results.
Key Financial Metrics
Key Facts
- Full-year 2025 revenue was $133.9 million, up 14% YoY
- Achieved $5.0 million net income in 2025, compared to a $16.5 million net loss in 2024
- Guided 2026 revenue to $95-$99 million, a significant decrease from 2025 due to divestitures and loss of license revenue
- Completed sale of Coflex/CoFix assets and international businesses to Companion Spine for $21.4 million
- Cash position increased to $17.3 million as of December 31, 2025, with an additional $10.5 million received post-year-end
Financial Impact
2026 revenue guidance of $95-$99 million represents a 26-29% decline from 2025's $133.9 million
Risk Factors
- Significant revenue decline expected in 2026 due to divestitures and cessation of license agreements
- Execution risk in growing the core biologics business to offset lost revenue streams
- Potential margin pressure as the company operates on a smaller revenue base
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-013788 |
| Document: form8-k.htm | 0001493152-26-013788 |
| Document: 0001493152-26-013788-index-headers.html | 0001493152-26-013788 |
| Document: 0001493152-26-013788-index.html | 0001493152-26-013788 |
| Document: 0001493152-26-013788.txt | 0001493152-26-013788 |
| 8-K Data (Synthetic) | 0001493152-26-013788 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 10w ago | 8-K | $0.3200 $0.3380 | ▼ −5.63% | ▼ −6.68% | $0.2751 (+14.03%) |
Apr 13, 2026 28w ago | 8-K | $0.4800 $0.5200 | ▲ +8.33% | ▲ +0.61% | $0.2751 (−42.69%) |
Mar 31, 2026 29w ago | 8-K | $0.5600 $0.5390 | ▼ −3.75% | ▼ −13.17% | $0.2751 (−50.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers